Aardvark Therapeutics, Inc. Common Stock (AARD)의 가격은 얼마입니까?

Aardvark Therapeutics, Inc. Common Stock (AARD)의 가격은 $7.22입니다.

Aardvark Therapeutics, Inc. Common Stock (AARD)의 시가 총액은 무엇입니까?

Aardvark Therapeutics, Inc. Common Stock (AARD)의 시가 총액은 $158.03M입니다.

Aardvark Therapeutics, Inc. Common Stock (AARD) PBR

Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.

연도	P/B 비율	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

P/B 비율

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	P/B 비율	P/B 비율 차이	국가
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
Moderna, Inc. MRNA.US	3.7087	-	US
CSL Limited CSL.AX	2.5054	-	AU
Lonza Group AG LONN.SW	-	-	CH

회사

P/B 비율

P/B 비율 차이

국가